Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

SSY Group Secures Global Rights to Pediatric Antispasmodic and COPD Drugs from Xinzheng Heying – Full IP Transfer in Category 2.2 and 2.3 Assets

Fineline Cube Jun 5, 2026
Company Deals

Lonza and Stipple Bio Forge Strategic ADC Partnership – Combining Epitope Discovery with Glyco Connect Platform for Next-Generation Oncology Therapies

Fineline Cube Jun 5, 2026
Company Deals

Gilead and Lakefront Complete $1.675B Acquisition of Ouro Medicines – Securing BCMAxCD3 T Cell Engager for Autoimmune Diseases

Fineline Cube Jun 5, 2026
Company Deals

Pfizer Licenses Chai Discovery’s AI Platform for Drug Discovery – Gains Early Access to Breakthrough Chai-3 Model for Antibody Design

Fineline Cube Jun 5, 2026
Company Deals

Everest Medicines Secures Asia-Pacific Rights to Mabworks’ Obexelimab β in $30.9M Deal – First-in-Class CD20 Antibody for NMOSD

Fineline Cube Jun 5, 2026
Policy / Regulatory

China’s NHC Releases Sixth Pediatric Drug Priority List – 27 Varieties Including Emicizumab, Pembrolizumab, and Omalizumab Targeted for Development

Fineline Cube Jun 5, 2026
Company Drug

Guangzhou Lupeng’s Rocbrutinib Receives NMPA Priority Approval for Relapsed/Refractory Mantle Cell Lymphoma – Fourth-Generation BTK Inhibitor Shows 63.9% Response Rate

Fineline Cube Jun 5, 2026
Company Drug

Sichuan Biokin Receives NMPA Go-Ahead for BL-M08D1 Bispecific Antibody in DLBCL Combination Therapy – ADC Leverages Proven BL-B01D1 Platform

Fineline Cube Jun 5, 2026
Company Drug

Abbisko Therapeutics’ ABSK021 Receives BTD for Giant Cell Tumor Treatment

Fineline Cube Jul 13, 2022

Shanghai-based Abbisko Therapeutics Co., Ltd (HKG: 2256) announced that its Category 1 drug ABSK021 has...

Policy / Regulatory

NMPA Reclassifies Glucosamine Sulfate to OTC, Mandates Label Revisions

Fineline Cube Jul 13, 2022

China’s National Medical Products Administration (NMPA) announced that potassium glucosamine sulfate has been reclassified from...

Policy / Regulatory

China’s JPO Launches VBP Round for Orthopedic Spine Consumables

Fineline Cube Jul 13, 2022

China’s Joint Procurement Office (JPO) announced plans on July 11 to conduct a volume-based procurement...

Company Drug

HutchMed’s Orpathys-Tagrisso Combo Shows Promise in NSCLC at WCLC

Fineline Cube Jul 13, 2022

China-based HutchMed (NASDAQ: HCM, HKG: 0013) announced the publication of an abstract detailing the SAVANNAH...

Company Drug

Junshi Biosciences’ JS203 Bispecific Antibody Receives NMPA Green Light for NHL Study

Fineline Cube Jul 13, 2022

China-based Junshi Biosciences (HKG: 1877, SHA: 688180) announced that the National Medical Products Administration (NMPA)...

Drug

Eli Lilly’s Trulicity + Insulin Combo Meets Goals in China’s AWARD-CHN3 Study

Fineline Cube Jul 13, 2022

Eli Lilly (NYSE: LLY) announced that its Phase III AWARD-CHN3 study of Trulicity (dulaglutide) combined...

Policy / Regulatory

China’s 7th VBP Round Yields 65.5% Drug Price Cuts, Foreign Firms Secure Bids

Fineline Cube Jul 13, 2022

China’s 7th national volume-based procurement (VBP) round concluded with winning bids averaging a 65.5% price...

Company Drug

CDE Grants Priority Review to Ascentage’s Olerembatinib and Roche’s Crovalimab

Fineline Cube Jul 12, 2022

The Center for Drug Evaluation (CDE) has granted priority review status to two drugs: Suzhou...

Company Deals

Athenex Sells China Subsidiaries to TiHe Capital for USD 19 Million

Fineline Cube Jul 12, 2022

US-based Athenex Inc. (Nasdaq: ATNX) announced an agreement to sell all equity interests in its...

Company Deals

Tasly Pharmaceuticals and Mauna Kea Form JV to Commercialize Cellvizio in China

Fineline Cube Jul 12, 2022

China-based Tasly Pharmaceuticals (SHA: 600535) announced a joint venture (JV) with France’s Mauna Kea Technologies...

Company Medical Device

MicroPort MedBot’s Honghu Robot Wins FDA 510(k) Certification for Joint Replacement

Fineline Cube Jul 12, 2022

Shanghai MicroPort MedBot (Group) Co., Ltd (HKG: 2252) announced that its in-house developed orthopedic surgery...

Company Medical Device

Venus Medtech’s Transcatheter Prosthetic Pulmonary Valve Approved by NMPA

Fineline Cube Jul 12, 2022

The National Medical Products Administration (NMPA) has approved Venus Medtech (Hangzhou) Inc’s (HKG: 2500) transcatheter...

Company Drug

Hengrui Medicine’s SHR-1701 + Ameile Combo Greenlit for EGFR-Mutated NSCLC Trial

Fineline Cube Jul 12, 2022

China-based Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276) announced that the National Medical Products Administration...

Company Drug

Eucure Biopharma Doses First Patient in YH003 + Keytruda Trial for Mucosal Melanoma

Fineline Cube Jul 12, 2022

Eucure Biopharma, a subsidiary of Sino-US contract research organization Biocytogen, announced that the first patient...

Company Drug

Overland ADCT BioPharma Launches Global Phase III Trial for Zynlonta in DLBCL

Fineline Cube Jul 12, 2022

Overland ADCT BioPharma, a joint venture between China’s Overland Pharmaceuticals and Switzerland’s ADC Therapeutics SA...

Company Drug

Bio-Thera Solutions Doses First Patient in BAT8006 Phase I Study for Solid Tumors

Fineline Cube Jul 12, 2022

Guangzhou-based Bio-Thera Solutions (SHA: 688177) announced that the first patient has been dosed in a...

Company Deals

Neurophth and Abogen Partner on mRNA Therapy for Retinal Diseases

Fineline Cube Jul 11, 2022

China-based Neurophth Biotechnology Ltd, a gene therapy specialist, has partnered with compatriot mRNA drug developer...

R&D

Hong Kong Researchers Explore TES for Depression and Alzheimer’s Treatment

Fineline Cube Jul 11, 2022

Researchers at The University of Hong Kong’s Li Ka Shing Faculty of Medicine (HKUMed) and...

Company

CASI Pharmaceuticals Invests in Precision Immune Therapeutics for CID-103 Development

Fineline Cube Jul 11, 2022

US-based CASI Pharmaceuticals Inc. (NASDAQ: CASI) announced the completion of a financing round for China’s...

Company

Sinopharm in Talks to Acquire BBI Life Sciences in USD 1B+ Deal

Fineline Cube Jul 11, 2022

China National Pharmaceutical Group Co., Ltd (Sinopharm) is reportedly considering a bid to acquire Shanghai-based...

Posts pagination

1 … 663 664 665 … 678

Recent updates

  • Guangzhou Lupeng’s Rocbrutinib Receives NMPA Priority Approval for Relapsed/Refractory Mantle Cell Lymphoma – Fourth-Generation BTK Inhibitor Shows 63.9% Response Rate
  • China’s NHC Releases Sixth Pediatric Drug Priority List – 27 Varieties Including Emicizumab, Pembrolizumab, and Omalizumab Targeted for Development
  • Sichuan Biokin Receives NMPA Go-Ahead for BL-M08D1 Bispecific Antibody in DLBCL Combination Therapy – ADC Leverages Proven BL-B01D1 Platform
  • Mabwell Bioscience Secures NMPA Clinical Approval for 9MW5211 in Inflammatory Bowel Disease – Highly Specific Depleting Antibody Targets Pathogenic Immune Cells
  • SSY Group Secures Global Rights to Pediatric Antispasmodic and COPD Drugs from Xinzheng Heying – Full IP Transfer in Category 2.2 and 2.3 Assets
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Guangzhou Lupeng’s Rocbrutinib Receives NMPA Priority Approval for Relapsed/Refractory Mantle Cell Lymphoma – Fourth-Generation BTK Inhibitor Shows 63.9% Response Rate

Policy / Regulatory

China’s NHC Releases Sixth Pediatric Drug Priority List – 27 Varieties Including Emicizumab, Pembrolizumab, and Omalizumab Targeted for Development

Company Drug

Sichuan Biokin Receives NMPA Go-Ahead for BL-M08D1 Bispecific Antibody in DLBCL Combination Therapy – ADC Leverages Proven BL-B01D1 Platform

Company Drug

Mabwell Bioscience Secures NMPA Clinical Approval for 9MW5211 in Inflammatory Bowel Disease – Highly Specific Depleting Antibody Targets Pathogenic Immune Cells

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.